NHF’s QMS is ISO 9001:2015 Certified

Government of Jamaica

NHF SUSPENDS SUBSIDIES FOR AMLODIPINE (AMLODIPINE PREPARATIONS TO BE REMOVED FROM NHF INDIVIDUAL BENEFITS PROGRAMMES)

NHF SUSPENDS SUBSIDIES FOR AMLODIPINE (AMLODIPINE PREPARATIONS TO BE REMOVED FROM NHF INDIVIDUAL BENEFITS PROGRAMMES)

The Board of the National Health Fund (NHF) has decided that it will suspend the subsidies that the Fund now offers for the drug Amlodipine and preparations containing Amlodipine. Amlodipine is one of the fifty-four (54) drugs for which the NHF provides a subsidy for the treatment of hypertension. The subsidy for Amlodipine was suspended on September 15, 2010.

As a result, the drug will be removed from NHF Individual Benefits List for NHFCard beneficiaries and Jamaica Drug for the Elderly Programme (JADEP) beneficiaries.

The decision is being made against the background that on April 29, 2009, the Jamaican Court granted an injunction against the sale and supply of two generic versions of Amlodipine available on the Jamaican market at that time. Consequently, the NHF removed those generics from its Individual Benefits Programmes but kept the branded source of Amlodipine, in the hope that the legal battle would have been quickly resolved. The NHF has had a thorough review of the situation and has reluctantly decided that the subsidy for Amlodipine should be suspended until the legal issues surrounding the matter are resolved.

The NHF regrets any inconvenience that this change may cause and would like to assure beneficiaries and providers that as soon as the legal issues have been resolved the Fund will review its position in relation to this drug.

For further information contact:
Rosemarie Lee tel. 906-1106 or 535-0909
Shermaine Robotham tel. 322- 0809

National Health Fund © 2024. All Rights Reserved.